"In these OAC-naive patients, asundexian was associated with a slight increase in stroke rates but demonstrated a lower risk ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Good morning, and welcome to Johnson & Johnson's First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference. This ...

Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, ...

“Her leadership will accelerate our mission to translate the novel mechanism of Rycals ® into ... Dr. Tarka was the Clinical Program Lead for Xarelto ® (rivaroxaban) at Janssen Pharmaceuticals ...

In early March, the FDA approved the first generics of the anticoagulant rivaroxaban 2.5 mg (Xarelto, Janssen/Bayer ... directly target the underlying mechanisms of cardiovascular events.” ...

BMS is a longstanding player in cardiovascular with drugs like Pfizer-partnered Eliquis (apixaban ... which are both based on novel mechanisms of action – have been keenly anticipated by ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

This means apixaban cut the clot risk by nearly half. It also improved the chances of keeping the vascular access working without further issues (32% failure rate versus 50% in the control group).

CHICAGO — Extended therapy with reduced-dose apixaban is just as effective as the high dose in preventing recurrent venous thromboembolism (VTE) in patients with active cancer who completed at ...

Extended treatment with low-dose apixaban was noninferior to a full dose for preventing cancer-related VTE. Perspective from Geoffrey Barnes, MD, MSc CHICAGO — For patients with cancer requiring ...